GAIN-THERAPEUTICS-SA
Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in central nervous system (CNS) diseases, today announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.
This grant will further strengthen Gain Therapeutics’s novel therapeutic approach for targeting rare diseases in the CNS, where lysosomal misfolded enzymes lead to sever clinical phenotypes, where no treatment is available and/or high unmet medical needs still do afflict patients, families and carers. This funding will support the development of the drugs portfolio of Gain Therapeutics for the treatment of Gaucher Disease, GM1 Gangliosidosis and Parkinson’s Disease.
“We are proud of the Eurostars-2 grant notification, where Gain Therapeutics’ platform technology for identifying structurally targeted allosteric regulators has been very positively evaluated due to: clear unmet medical needs (and namely orphan, rare and defined diseases with a strong neurological need still unmet); novel platform technology developing brain penetrant small molecules able to restore misfolded lysosomal enzyme; a clearly defined path into a significant market; a balanced yet ambitious project with a strong IP estate,” said Dr. Manolo Bellotto, General Manager of Gain Therapeutics SA.
“The excellent ranking of our consortium as 2nd best among over 325 eligible consortia from all over Europe is also a rewarding recognition for our long-standing activity in the field of rare diseases. The transnational collaboration with Gain Therapeutics and Neuro-Sys will hopefully offer the opportunity to translate into the clinics, the research activity performed at the IRB and aiming at understanding how perturbations in protein folding may cause severe diseases” said Dr. Maurizio Molinari, Group leader at the IRB, Bellinzona and Adjunct Professor at the École Polytechnique Fédérale de Lausanne (EPFL).
“The innovative scientific approach of the project has strongly motivated us to get involved. The remarkable ranking at European level clearly demonstrates Europe's interest in developing innovative cures for orphan indications. The collaboration with Gain Therapeutics and IRB on this ambitious project is a great opportunity to develop innovative platforms and to get a better understanding of the mechanisms of these rare diseases.” said Dr. Noelle Callizot, CSO and General Manager of Neuro-Sys SAS.
About Gain Therapeutics SA
Gain Therapeutics SA is a Swiss biotech company specializing in the discovery of new drugs for rare and CNS diseases. The company targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs. Gain Therapeutics SA is developing a new class of compounds: structurally targeted allosteric regulators, identified through its pioneering proprietary platform – SEE-Tx.
https://www.gaintherapeutics.com/
About Institute for Research in Biomedicine
Founded in 2000 in Bellinzona, the IRB is affiliated with the Università della Svizzera italiana, since 2010. IRB hosts 13 research groups studying defense mechanisms to fight infections, tumors and degenerative diseases. With more than 630 publications in main scientific journals, the IRB has gained international recognition as a center of excellence for immunology and cell biology. Molinari’s laboratory investigates the protein quality control processes determining whether a polypeptide should be secreted, retained in the ER, or selected for degradation. Particular emphasis is given to the study of select rare diseases such as α1-antitrypsin deficiency, LSDs and Charcot-Marie-Tooth 1B neuropathy.
About Neuro-Sys
Neuro-Sys is expert in preclinical in vitro models of neurodegenerative and neurological diseases. It has developed specific models to accurately determine the pharmacological profiling of lead compounds and explore their underlying mechanism of action and to determine the therapeutic indication. With a great team of experts in pharmacology and drug development and an innovative proprietary automated medium throughput platform combined with advanced models, it provides predictable results and a unique approach in the neurodegenerative diseases research. The company’s many loyal pharma and biotech customers around the world are the best testimony to the efficiency and reliability of its solution.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190722005034/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PPG celebrates 3,000th installation of PPG MOONWALK paint mixing system at U.S. collision center14.8.2025 20:01:00 CEST | Press release
PPG (NYSE: PPG) today announced that it has completed the 3,000th global installation of its PPG MOONWALK® automated paint mixing system at Wren’s Collision Group’s facility in Auburn, Ala. Since its launch in 2019, the PPG MoonWalk system has transformed body shop operations worldwide by delivering exceptional accuracy, traceability and productivity across the automotive repair process. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814323910/en/ “We are proud to be a part of this innovation in the automotive industry with the installation of the 3,000th PPG MoonWalk system at our newest body shop,” said James Wren, owner of Wren’s Collision Group, at a celebration of the milestone held in July. “With our new Auburn facility, we are looking forward to continuing to drive productivity, efficiency, and profit throughout the 19 body shops we own. We are excited to be a part of this milestone for PPG as a long-standing partn
Xsolla Expands Payment Coverage in Europe to Unlock New Market Potential for Game Developers With Bizum, Swish, and Satispay14.8.2025 18:00:00 CEST | Press release
New Payment Methods Give Game Developers Localized, Mobile-First Checkout Options In Spain, Sweden, And Italy Xsolla, a global commerce company helping developers launch, grow and monetize their games, announces today the expansion of its payments solution across Europe with the launch of new regionally preferred methods: Bizum in Spain, Swish in Sweden, and Satispay in Italy. These integrations via Xsolla Pay Station enable game developers and publishers to offer secure, seamless, and familiar checkout flows across three of the region’s fastest-growing digital economies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814474025/en/ (Graphic: Xsolla) The European gaming market is expected to generate nearly $85 billion in 2025 and grow to over $112 billion by 2029. As mobile and app-native payment preferences continue to rise globally, players are increasingly demanding fast, secure, and culturally aligned payment options.
Eurazeo Enters Into Exclusive Discussions With INSPIRED PET NUTRITION Regarding the Sale of Its Stake in Ultra Premium Direct14.8.2025 17:40:00 CEST | Press release
Eurazeo has entered into exclusive discussions with INSPIRED PET NUTRITION (“IPN”), the fast-growing international pet food company controlled by CapVest Partners LLP (“CapVest”), regarding the sale of Ultra Premium Direct (“UPD”), France’s leading direct-to-consumer (D2C) online pet food company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814809542/en/ Ultra Premium Direct product Founded in 2013, UPD has established itself as a leading player in the French premium pet food market and is now recognised as the top direct-to-consumer (D2C) online brand in the segment, recognised for its exceptional customer experience and already serving over 285k active customers. UPD combines high-quality, veterinarian-developed products with a direct factory-to-consumer model, offering a unique premium yet affordable proposition. Leveraging its data-driven approach, the company is now building a powerful omnichannel strategy to furt
Tyk Scales up in US Financial Sector, as Banks Lean on APIs as Revenue-Driving Infrastructure14.8.2025 17:24:00 CEST | Press release
AI-ready API management company Tyk has announced the appointment of three new senior leaders, as it strengthens its support for banks in the US financial sector. The strategic appointments come as banks increasingly evolve their use of APIs towards monetization. Martin Buhr, Founder and CEO of Tyk, which specializes in providing practical blueprints for integrating AI in a way that’s well-governed, efficient, and future-ready, explains: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814736978/en/ Tyk scales up in US financial sector “Just a couple of years ago, banks were coming to us focused on basic authentication and control requests. Now, it’s becoming the norm for them to use APIs to underpin new monetization strategies, as well as seamless regulatory compliance. We’ve helped leading global banks make the change and are excited to have three API industry veterans – Mark Gurvis, Laura Heritage and Kuldeepak Angrish –
LambdaTest Unveils Media Injection for Real Device Testing14.8.2025 17:00:00 CEST | Press release
Innovative camera simulation feature enables robust testing of image and video capture workflows across 10,000+ real mobile devices LambdaTest, a unified agentic AI and cloud engineering platform, has launched Video Injection capability in Media Injection for real device testing, bringing powerful support for testing camera and video-based app functionalities at scale. This new capability empowers developers and QA teams to simulate image and video capture scenarios on real Android and iOS devices, unlocking comprehensive validation for camera-driven app experiences. With Media Injection, users can test key workflows like QR code and barcode scanning, digital check processing, real-time video streaming, and photo or video upload features, directly on physical devices. This is made possible through LambdaTest’s proprietary Sensor Instrumentation technology, which seamlessly injects simulated media into the app’s camera interface, bypassing the need for physical camera use while ensuring
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom